Cargando…

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury

Myeloproliferative neoplasms are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell expansion. The acquired kinase mutation JAK2V617F plays a central role in these disorders. Abnormalities of the marrow microenvironment are beginning to be recognized as an important facto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chi Hua Sarah, Zhang, Yu, Kaushansky, Kenneth, Zhan, Huichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029534/ https://www.ncbi.nlm.nih.gov/pubmed/29567773 http://dx.doi.org/10.3324/haematol.2017.185736

Ejemplares similares

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms
por: Zhan, H, et al.
Publicado: (2018)

Megakaryocytes as the Regulator of the Hematopoietic Vascular Niche
por: Zhan, Huichun, et al.
Publicado: (2022)

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm
por: Zhang, Haotian, et al.
Publicado: (2021)

Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm
por: Castiglione, Melissa, et al.
Publicado: (2020)

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms
por: Yokokawa, Tetsuro, et al.
Publicado: (2021)

Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP
por: Zhang, Haotian, et al.
Publicado: (2023)

Hematopoietic JAK2(V617F)-mediated clonal hematopoiesis: AIM2 understand mechanisms of atherogenesis
por: Sano, Soichi, et al.
Publicado: (2021)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative neoplasm
por: Zhang, Haotian, et al.
Publicado: (2021)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation
por: Langabeer, Stephen E.
Publicado: (2017)

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F
por: Lundberg, Pontus, et al.
Publicado: (2014)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

Platelets prime hematopoietic–vascular niche to drive angiocrine-mediated liver regeneration
por: Shido, Koji, et al.
Publicado: (2017)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?
por: Liu, Kenneth G., et al.
Publicado: (2016)

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
por: Yang, Yue, et al.
Publicado: (2023)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

International external quality assurance of JAK2 V617F quantification
por: Asp, Julia, et al.
Publicado: (2018)

The JAK2 V617F mutation in retinal vein or artery occlusion
por: Langabeer, Stephen E.
Publicado: (2019)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

CD169(+) macrophages provide a niche promoting erythropoiesis under homeostasis, myeloablation and in JAK2V617F-induced polycythemia vera
por: Chow, Andrew, et al.
Publicado: (2013)

JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells
por: Wolf, Alexandra, et al.
Publicado: (2013)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion
por: Kent, David G., et al.
Publicado: (2013)

Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
por: Lee, Jong-Mi, et al.
Publicado: (2023)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
por: Zaleskas, Virginia M., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_9d496a8i39an60fp7a89rmloge